THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

In a groundbreaking new study, Ozempic was found to be so effective at treating arthritis that people no longer needed treatment.